Agios Pharma (0HB0) AI Stock Analysis

Company Guidance

Agios reiterated concrete 2026 targets and near‑term operational plans: Q2 Mitapivat net revenue was $44.7M (U.S. $40.9M; ex‑U.S. $3.8M), cost of sales $3M, R&D $100.8M (vs. $91.9M y/y, reflecting a ~$25M upfront in‑licensing payment), SG&A $51.5M and a net loss of $100.7M, with approximately $1.0B in cash, cash equivalents and marketable securities at quarter end. For 2026 the company expects roughly $45–50M of U.S. PK deficiency revenue, full‑year operating expenses to be approximately flat versus 2025 excluding the $25M upfront payment, and gross‑to‑net of ~10–20% (quarter‑to‑quarter variability). Commercial metrics and launch guidance include 442 cumulative AQVESME prescriptions as of June 30 (up ~200 in Q2), ~75% thalassemia lives covered by payer policies, time‑to‑start trending toward a 10–12 week range, and Q2 revenue including an estimated ~$5M one‑time stocking benefit; Agios is targeting an initial ~25,000 patient sickle cell population and is preparing for a Nov. 1 PDUFA (Mitapivat sNDA, priority review). Pipeline and operational guidance: AG‑236 moving into a seamless Phase II/III program with Phase II starts planned H2 2026, cevidoplenib in‑licensed with the upfront recognized in Q2 and progression toward Phase III planned, REIGNITE Phase III dosing underway, and AG‑181 PKU Phase Ib proof‑of‑mechanism data expected in H2 2026.